Dr. Motzer discusses the future of nccRCC management and emerging data or unmet needs he is following.
Bladder Cancer Indication of Sacituzumab Govitecan Withdrawn in US
Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the agent in consultation with the FDA.
Read More
Transforming Prostate Cancer Care Through Personalized Medicine
Adam Weiner, MD, discusses his journey toward becoming an oncologist with a focus in urology in this episode of Emerging Experts.
Listen
Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC
Yousef Zakharia, MD, discussed some of the available combination therapies for non–clear cell renal cell carcinoma treatment.
Dizman’s Global Pursuit to Cancer Research and Understanding
In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.
FDA Clears NDA of Intravesical Mitomycin in Non–Muscle-Invasive Bladder Cancer
A Prescription Drug User Fee Act target action date of June 13, 2025, has been set for the new drug application of intravesical mitomycin.
Roundtable Roundup: First and Second Choices for Frontline RCC Therapy
During separate virtual live events, David A. Braun, MD, PhD, and Rana R. McKay, MD, surveyed oncologists on options for a patient with clear cell renal cell carcinoma (RCC) in the front line.